Gerald Cochran, MSW, PhD

Journal Article

1. Broussard G, Hohmeier K, Field C, Gordon AJ, Carlston K, Cernasev A, Tyszko M, Snyder A, Cochran G (In press). Barriers and Facilitators to the Implementation of Screening and Intervention for Co-use Opioid Medications and Alcohol among Community Pharmacy Patients. . J Subst Abuse Treat.
2. Cochran G, Brown J, Yu Z, Gordan A, Frede S, Hardy C, Castora-Binkley M, Homested F, Marsch L, Holtyn A, Winhusen TJ (2024). CTN-0138: Adaptation, Implementation, and Cluster Randomized Trial of a Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool—A Protocol Paper. Addict Sci Clin Pract.
3. Hardy, C, Jaggers, J, Lundahl, B, Gass, M, Osteen, P, Cochran, G (In press). Perceptions of youth transport in wilderness therapy. Resid Treat Child Youth.
4. Franks L, Cochran G, Reeves C, Incze MA, Hardy CJ, Gordon AJ, Kelley AT (In press). Evaluations of state medical cannabis programs in the US: A narrative review. . Med Cannabis Cannabinoids.
5. Song K, Amuan M, Adams R, Kennedy E, Gordon AJ, Carlson K, Pogoda T, Meyer E, Cochran G, Spevak C, Pugh MJ (In press). Diagnosis of Alcohol Use Disorder and Deaths Related to Alcohol, Drug Overdose, or Suicide among Post-9/11 Active Duty Service Members and Veterans Following Traumatic Brain Injury. J Addict Med.
6. Nguyen K, Wilson DL, Diiulio J, Hall B, Militello L, Gellad WF, Harle CA, Lewis M, Schmidt S, Rosenberg EI, Nelson D, He X, Wu Y, Bian J, Staras SAS, Gordon AJ, Cochran G, Kuza C, Yang S, Lo-Ciganic W (2024). Design and development of a machine-learning-driven opioid overdose risk prediction tool integrated in electronic health records in primary care settings. Bioelectron Med, 18(10).
7. Hafen K, Wallace H, Fritz K, Fordham C, Haskell T, Kelley AT, Jones AL, Cochran G, Gordon AJ (2024). A novel rural hospital/clinic-system practice-based research network: the rural addiction implementation network (RAIN) initiative and its goals, implementation, and early results. Am J Drug Alcohol Abuse.
8. Pugh MJ, Haun JN, White PJ, Cochran G, Mohanty AF, McAndrew LM, Gordon AJ, Nelson RE, Vanneman ME, Naranjo DE, Benzinger RC, Jones AL, Kean J, Zickmund SL, Fagerlin A (2024). Developing Evidence to Support Policy: Protocol for the StrAtegic PoLicy EvIdence-Based Evaluation CeNTer (SALIENT). JMIR Res Protoc, 13, e59830. (Read full article)
9. Seliski N, Madsen T, Eley E, Colosimo J, Engar E, Gordon A, Barnett G, Humiston G, Morsillo T, Stolebarger L, Smid MC, Cochran G (2024). Implementation of a Rural Emergency Department-Initiated Buprenorphine Program in the Mountain West: A Study Protocol. Addict Sci Clin Pract.
10. Smid, MC, Seliski N, Charles JE, Castro S, Humiston E, Cash E, Allshouse A, Turner E, Carlston K, Gibson M, Gordon AJ, Cochran G (2024). Prevention of postpartum methamphetamine use with micronized progesterone trial (PROMPT): A pilot randomized controlled trial protocol. Contemp Clin Trials Commun.
11. McLeman B Gauthier P Lester LS Homsted F Gardner V Moore SK Joudrey PJ Saldana L Cochran G Harris J Hefner K Chongsi E Kramer K Vena A Ottesen R Gallant T Boggis J Rao D Page M Cox N Iandiorio M Ambaah E Ghitza E Fiellin DA Marsch LA (2024). Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder in Primary Care: Study Design and Methodological Considerations. Addict Sci Clin Pract, 19(1).
12. Cochran G, Smid MC, Krans EE, Yu Z, Carlston K, White A, Abdulla W, Baylis J, Charron E, Okifugi A, Gordon AJ, Lundahl B, Silipigni J, Seliski N, Haaland B, Tarter R (2023). Patient navigation for pregnant individuals with opioid use disorder: Results of a randomized multi-site pilot trial. Addiction, 119(3), 544-556. (Read full article)
13. Hohmeier KC, Cernasev A, Leibold C, Moore TM, Schlesinger E, Arce I, Geminn W, Chisholm-Burns M, Cochran G (2023).  Patient reported goals for medications for opioid use disorder: A theory of proximal goal attainment. Explor Res Clin Soc Pharm, 12.
14. Smid MC, Charron E, AA Allshouse AA, Campbell K, Metz TD, Debbink MP, Cochran G (2023). Co-occurring opioid and methamphetamine use disorder and severe maternal morbidity and mortality in Utah. . Am J Obstet Gynecol MFM.
15. Bridges NC, Taber R, Foulds AL, Bear TM, Cloutier RM, McDonough BL, Gordon AJ, Cochran GT, Donohue JM, Adair D, DiDomenico E, Pringle JL, Gellad WF, Kelley D, Cole ES (2023). Medications for opioid use disorder in rural primary care practices: Patient and provider experiences. J Subst Use Addict Treat, 154, 209133. (Read full article)
16. Jarrett JB, Bratberg J, Burns AL, Cochran G, DiPaula BA, Legreid Dopp A, Elmes A, Green TC, Hill LG, Homsted F, Hsia SL, Matthews ML, Ghitza UE, Wu LT, Bart G (2023). Research Priorities for Expansion of Opioid Use Disorder Treatment in the Community Pharmacy. Subst Abus, 44(4), 264-276. (Read full article)
17. Charron E, Brooks JH, Peterson KT, Akinwolere OG, Winhusen T, Cochran G (2023). Mapping prescription drug monitoring program data to self-report measures of non-medical prescription opioid use in community pharmacy settings. Res Social Adm Pharm, 19(8), 1171-1177. (Read full article)
18. Cernasev A, Hohmeier K, Field C, Gordon AJ, Elliott S, Carlston K, Broussard G, Cochran G (2023). Co-use of Opioid Medications and Alcohol Prevention Study (COAPS). Subst Abus, 44(3), 130-135. (Read full article)
19. Charles JE, Baylis J, Smid MC, Cochran G (2023). Nonfatal Overdoses Among Pregnant Individuals With Opioid Use Disorder. Obstet Gynecol, 141(5), 961-963. (Read full article)
20. Charron E, White A, Carlston K, Abdullah W, Baylis JD, Pierce S, Businelle MS, Gordon AJ, Krans EE, Smid MC, Cochran G (2023). Prospective Acceptability of Digital Phenotyping among Pregnant and Parenting People with Opioid Use Disorder: A Multisite Qualitative Study. Front Psychiatry.
21. Hohmeier KC, Cernasev A, Leibold C, Moore TM, Schlesinger E, Cochran G, Arce I, Geminn W, Chisholm-Burns M (2023). Community-Centered Patient Journey Map in Opioid Use Disorder: A Tool to Address Compassion Fatigue among Community Pharmacists. Pharmacy (Basel), 11(2). (Read full article)
22. Cloutier RM, Cole ES, McDonough BL, Lomauro DA, Miller JP, Talbert AL, Bear TM, Bridges NC, Foulds AL, Taber R, Gordon AJ, Cochran GT, Kmiec J, Donohue JM, Kelley D, DiDomenico E, Adair D, Pringle JL (2023). Strategies to recruit rural primary care providers to implement a medication for opioid use disorder (MOUD) focused integrated care model. Implement Res Pract, 4, 26334895231152808. (Read full article)
23. Charron E, Yu Z, Lundahl B, Silipigni J, Okifuji A, Gordon AJ, Baylis JD, White A, Carlston K, Abdullah W, Haaland B, Krans EE, Smid MC, Cochran G (2023). Cluster analysis to identify patient profiles and substance use patterns among pregnant persons with opioid use disorder. Addict Behav Rep, 17, 100484. (Read full article)
24. Magel J, Hartman P, Fritz JM, Koch NN, Dostal H, Vollmer N, Ferguson NL, Tapken J, Cohee K, Cochran G, Gordon AJ (2023). Patients' Perceptions of Physical Therapists Addressing Opioid Misuse. Subst Abus, 44(1), 32-40. (Read full article)
25. Guo J, Gellad WF, Yang Q, Weiss JC, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Kuza CC, Wilson DL, Lo-Ciganic WH (2022). Changes in predicted opioid overdose risk over time in a state Medicaid program: a group-based trajectory modeling analysis. Addiction, 117(8), 2254-2263. (Read full article)
26. Charron E, Okifuji A, Bryan MA, Reese S, Brown JL, Ferguson A, Ghitza UE, Winhusen T, Cochran G (2022). Pain Severity and Interference and Substance Use Among Community Pharmacy Patients Prescribed Opioids: A Secondary Analysis of the PHARMSCREEN Study. J Pain, 23(8), 1448-1459. (Read full article)
27. Smid MC, Allshouse AA, McMillin GA, Nunez K, Cavin T, Worden J, Buchi K, Muniyappa B, Varner MW, Cochran G, Metz TD (2022). Umbilical Cord Collection and Drug Testing to Estimate Prenatal Substance Exposure in Utah. Obstet Gynecol, 140(2), 153-162. (Read full article)
28. Magel J, Bishop MD, Lonnemann E, Cochran G, Fritz JM, West N, Gordon AJ (2021). The association between advanced orthopedic certification and confidence and engagement in prescription opioid medication misuse management practices: a cross-sectional study. J Man Manip Ther, 30(4), 228-238. (Read full article)
29. Kraemer KL, Althouse AD, Salay M, Gordon AJ, Wright E, Anisman D, Cochran G, Fischer G, Gellad WF, Hamm M, Kern M, Wasan AD (2022). Effect of Different Interventions to Help Primary Care Clinicians Avoid Unsafe Opioid Prescribing in Opioid-Naive Patients With Acute Noncancer Pain: A Cluster Randomized Clinical Trial. JAMA Health Forum, 3(7), e222263. (Read full article)
30. Lo-Ciganic WH, Donohue JM, Yang Q, Huang JL, Chang CY, Weiss JC, Guo J, Zhang HH, Cochran G, Gordon AJ, Malone DC, Kwoh CK, Wilson DL, Kuza CC, Gellad WF (2021). Developing and validating a machine-learning algorithm to predict opioid overdose in Medicaid beneficiaries in two US states: a prognostic modelling study. Lancet Digit Health, 4(6), e455-e465. (Read full article)
31. Kelley AT, Smid MC, Baylis JD, Charron E, Begaye LJ, Binns-Calvey A, Archer S, Weiner S, Pettey W, Cochran G (2022). Treatment access for opioid use disorder in pregnancy among rural and American Indian communities. J Subst Abuse Treat, 136, 108685. (Read full article)
32. Cochran G, Charron E, Brown JL, Cernasev A, Hohmeier KC, Winhusen TJ (2022). Risky alcohol use among patients dispensed opioid medications: A clinical community pharmacy study. Drug Alcohol Depend, 234, 109406. (Read full article)
33. Cochran G, Shen J, Cox N, Field C, Carlston K, Sengpraseut B, White A, Okifuji A, Jackman C, Haaland B, Ragsdale R, Gordon AJ, Tarter R (2022). Addressing opioid medication misuse at point of service in community pharmacy: A study protocol for an interdisciplinary behavioral health trial. Contemp Clin Trials, 116, 106759. (Read full article)
34. Brown JL, Cochran G, Bryan MA, Charron E, Winhusen TJ (2022). Associations between elevated depressive symptoms and substance use, prescription opioid misuse, overdose history, pain, and general health among community pharmacy patients prescribed opioids. Subst Abuse, 43(1), 1110-1115.
35. Cochran G, Cole ES, Sharbaugh M, Nagy D, Gordon AJ, Gellad WF, Pringle J, Bear T, Warwick J, Drake C, Chang CH, DiDomenico E, Kelley D, Donohue J (2021). Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder. J Addict Med, 16(2), e87-e96. (Read full article)
36. Carter G, Yu Z, Aryana Bryan M, Brown JL, Winhusen T, Cochran G (2021). Validation of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool with the WHO alcohol, smoking, and substance Involvement screening test (ASSIST). Addict Behav, 126, 107178. (Read full article)
37. Magel JJ, Cochran G, West N, Fritz JM, Bishop MD, Gordon AJ (2021). Physical therapists' attitudes are associated with their confidence in and the frequency with which they engage in prescription opioid medication misuse management practices with their patients. A cross-sectional study. Subst Abus, 43(1), 433-441. (Read full article)
38. Bryan MA, Mallik D, Cochran G, Lundahl B (2022). Mindfulness and Savoring: A Commentary on Savoring Strategies and Their Implications for Addiction Treatment. Subst Use Misuse, 57(5), 822-826. (Read full article)
39. Baylis JD, Charron E, Archer S, Garets M, Bryan MA, Foringer J, Kelley AT, Smid MC, Cochran G (2022). Attitudes, self-efficacy, and practices related to opioid risk assessment and mitigation: A comparison of health care professionals in rural communities. Subst Abus, 43(1), 1163-1171. (Read full article)
40. Hruschak V, Rosen D, Tierney M, Eack SM, Wasan AD, Cochran G (2021). Integrated Psychosocial Group Treatment: A Randomized Pilot Trial of a Harm Reduction and Preventive Approach for Patients with Chronic Pain at Risk of Opioid Misuse. Pain Med, 22(9), 2007-2018. (Read full article)
41. Cochran G, Brown J, Yu Z, Frede S, Bryan A, Ferguson A, Bayyari N, Snyder M, Charron E, Ghitza U, Olatunde L, Winhusen T (2021). Validation and Threshold Identification of a Prescription Drug Monitoring Program Clinical Opioid Risk Metric with the WHO Alcohol, Smoking, and Substance Involvement Screening Test Drug and Alcohol Dependence. Drug Alcohol Depend, 228, 1-8.
42. Hruschak VJ, Yuan Y, Ringwald W, Beaugard C, Repine M, Pacella-LaBarbara M, Rosen D, Cochran G (2020). Pain Appraisals in Patients with Physical Injury: Assessing the Role of Distress Tolerance in the Relationship between Depression and Pain Catastrophizing. Health Soc Work, 46(3), 187-198. (Read full article)
43. Bryan MA, Charron E, Adeoye-Olatunde O, Brown J, Ghitza U, Winhusen TJ, Cochran G (2021). Concomitant cannabis misuse and associations with depression, pain and substance misuse among patients prescribed opioids. Pharmacy (Basel), 9(3), 134.
44. Kelley AT, Smid MC, Baylis JD, Charron E, Binns-Calvey AE, Archer S, Weiner SJ, Begaye LJ, Cochran G (2021). Development of an unannounced standardized patient protocol to evaluate opioid use disorder treatment in pregnancy for American Indian and rural communities. Addict Sci Clin Pract, 16(1), 40. (Read full article)
45. Hohmeier K, Cernasev A, Sensmeier M, Hall E, Webb K, Barenie R, Cochran G (2021). U.S. Student Pharmacist Perceptions of the Pharmacists Role in Methadone for Opioid Use Disorder: A Qualitative Study. SAGE Open Med, 9, 1-7.
46. Kenney A, Cox N, Bryan M, Cochran G (2021). Brief intervention medication therapy management: The establishment of an opioid misuse intervention model delivered in community pharmacy. Am J Health Syst Pharm, 78(4), 310-319.
47. Gadd S, Cox N, Samuelson J, Kenney A, Turner K, Cochran G (2021). Abuse-Deterrent Opioid Formulations and the Opioid Crisis: A Pharmacist's Perspective. Ther Drug Monit, 43, 35-41.
48. Cole E, Drake C, DiDomenico E, Sharbaugh M, Kim JY, Nagy D, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CC-H, Kmiec J, Kelley D, Donohue JM (2021). Patterns of Clinic Switching and Continuity of Medication for Opioid Use Disorder in a Medicaid-Enrolled Population. Drug Alcohol Depend, 221, 108633.
49. Guo J, Lo-Ciganic W-H, Yang Q, Huang J, Weiss J, Cochran G, Malone D, Kuza CC, Gordon AJ, Donohue J, Gellad W (2021). Predicting Mortality Risk after a Hospital or Emergency Department Visit for Nonfatal Opioid Overdose. J Gen Intern Med, 36(4), 908-915.
50. Bryan MA, Smid M, Cheng M, Fortenberry K, Kenney A, Muniyappa B, Pendergrass D, Gordon A, Cochran, G (2020). Perinatal care and medication for opioid use disorder (MOUD) in rural Utah: A study protocol. Addict Sci Clin Pract, 15(33), 1-14.
51. Tarter R, Kirisci L, Cochran G, Seybert A, Reynolds M, Vanyukov M (2020). Forecasting Opioid Use Disorder at 25 Years of Age in 16-Year Old Adolescents. J Pediatr, 225, 207-213.el.
52. Lo-Ciganic WH, Huang J, Zhang HH, Weiss J, Kwoh K, Donohue J, Gordon A, Cochran G, Malone D, Kuza C, Gellad W (2020). Using machine learning to predict risk of incident opioid use disorder among fee-for-service Medicare beneficiaries: A prognostic study. PLoS One, 15(7), e0235981.
53. Kirisci L, Tarter R, Reynolds M, Hayes K, Cochran G, Vanyukov M (2020). Derivation and Assessment of the Opioid Use Disorder Severity Scale: Prediction of Health, Psychological and Social Adjustment Problems. Am J Drug Alcohol Abuse, 46(6), 699-707.
54. Sharareh N, Hess R, White S, Dunn A, Singer P, Cochran G (2020). A Vulnerability Assessment for the HCV Infections Associated with Injection Drug Use. Prev Med, 134, 106040.
55. Webb K, Cernasev A, Li M, Gatwood J, Cochran G, Hohmeier K (2021). An exploratory study of pharmacist perceptions of opioid interventions for acute pain. J Pharm Technol, 37(1), 36-44.
56. Cochran G, Smid M, Krans EE, Bryan MA, Gordon AJ, Lundahl B, Silipigni J, Haaland B, Tarter T (2019). A Pilot Multisite Study of Patient Navigation for Pregnant Women with Opioid Use Disorder  . Contemp Clin Trials, 87, 105888.
57. Hruschak V, Hildebrand A, Cochran G (2019). Psychiatric Comorbidity and Co-occurring Opioid Misuse: Depression Mediates the Relationship between Post-Traumatic Stress Disorder and Opioid Misuse in Community Pharmacy Settings. Subst Abus, 41(1), 77-84.
58. Cochran G, Chen Q, Field C, Seybert A, Hruschak V, Jaber A, Gordon AJ, Tarter R (2019). A community pharmacy-led intervention for opioid medication misuse: A small-scale randomized clinical trial. Drug Alcohol Depend, 205, 107570.
59. Lobo C, Cochran G, Chang J, Gellad W, Gordon AJ, Jalal H, Ciganic J, Kelley D, Donohue JM (2020). Associations between the specialty of opioid prescribers and opioid addiction, misuse and overdose outcomes. Pain Med, 21(9), 1871-1890.
60. Cochran G, Pacella M, Ringwald W, Repine M, Hruschak V, Beaugard C, Sewall C, Rosen D, Alarcon LH, Tarkin IS, Moloney GB, Corcos A (2020). Opioid use patterns and risk characteristics among injured patients. Subst Abus, 41(1), 24-28.
61. Moyo P, Gellad W, Sabik L, Cochran G, Cole E, Kelley D, Donohue J (2019). Opioid Prescribing Safety Measures in Medicaid Enrollees with and without Cancer. Am J Prev Med, 57(4), 540-544.
62. Cochran G, Cole E, Warwick J, Donohue J, Gordon A, Gellad W, Bear T, Kelley D, DiDomenico E, Pringle J (2019). Rural Access to MAT in Pennsylvania (RAMP): A Hybrid Implementation Study Protocol for Medication Assisted Treatment Adoption among Rural Primary Care Providers. Addict Sci Clin Pract, 14(1), 25.
63. Lindley B, Cox N, Cochran G (2019). Screening tools for detecting problematic opioid use and potential application to community pharmacy practice: A review. Integr Pharm Res Pract, 8, 85-96.
64. Hruschak V, Cochran G, Wasan A (2018). Psychosocial interventions for chronic pain and comorbid opioid misuse: a narrative review of the literature. J Opioid Manag, 14(5), 345-358.
65. Cole ES, DiDomenico E, Cochran G, Gordon AJ, Gellad WF, Pringle J, Warwick J, Chang CH, Kim JY, Kmiec J, Kelley D, Donohue JM (2019). The Role of Primary Care in Improving Access to Medication-Assisted Treatment for Rural Medicaid Enrollees with Opioid Use Disorder. J Gen Intern Med, 34(6), 936-943. (Read full article)
66. Bhardwaj SB, Cochran G, Kmiec J (2019). Opioid overdose history and awareness of naloxone in patients seeking outpatient detoxification. J Opioid Manag, 15(3), 253-259. (Read full article)
67. Lo-Ciganic WH, Huang JL, Zhang HH, Weiss JC, Wu Y, Kwoh CK, Donohue JM, Cochran G, Gordon AJ, Malone DC, Kuza CC, Gellad WF (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Netw Open, 2(3), e190968. (Read full article)
68. Theisen KM, Myrga JM, Hale N, Cochran G, Sewall C, Macleod LC, Jacobs BL, Davies BJ (2018). Excessive Opioid Prescribing After Major Urologic Procedures. Urology, 123, 101-107. (Read full article)
69. Rosen D, Engel RJ, Beaugard C, Davis N, Cochran G (2018). Baby Boomer's Substance Abuse and Researcher Indifference. J Gerontol Soc Work, 62(1), 16-28. (Read full article)
70. Hruschak V, Cochran G (2018). Psychosocial predictors in the transition from acute to chronic pain: a systematic review. Psychol Health Med, 23(10), 1151-1167. (Read full article)
71. Hruschak V, Cochran G, Wasan AD (2018). Psychosocial interventions for chronic pain and comorbid prescription opioid use disorders: A narrative review of the literature. J Opioid Manag, 14(5), 345-358. (Read full article)
72. Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Cole E, Lobo C, Frazier W, Zheng P, Chang CH, Kelley D, Donohue JM (2019). Prescription Opioid Quality Measures Applied Among Pennsylvania Medicaid Enrollees. J Manag Care Spec Pharm, 24(9), 875-885. (Read full article)
73. Tarter RE, Cochran G, Reynolds M (2018). Prevention of Opioid Addiction. 20(1), 38-60.
74. Ylioja T, Cochran G, Woodford MR, Renn KA (2018). Frequent Experience of LGBQ Microaggression on Campus Associated With Smoking Among Sexual Minority College Students. Nicotine Tob Res, 20(3), 340-346. (Read full article)
75. Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, Hruschak V, Chickering S, Kincman J, Jaber A, Tarter R (2017). A community pharmacy intervention for opioid medication misuse: A pilot randomized clinical trial. J Am Pharm Assoc (2003), 58(4), 395-403. (Read full article)
76. Cochran GT, Hruschak V, Abdullah W, Krans E, Douaihy AB, Bobby S, Fusco R, Tarter R (2018). Optimizing Pregnancy Treatment Interventions for Moms (OPTI-Mom): A Pilot Study. J Addict Med, 12(1), 72-79. (Read full article)
77. Ylioja T, Reddy V, Ambrosino R, Davis EM, Douaihy A, Slovenkay K, Kogut V, Frenak B, Palombo K, Schulze A, Cochran G, Tindle HA (2017). Using Bioinformatics to Treat Hospitalized Smokers: Successes and Challenges of a Tobacco Treatment Service. Jt Comm J Qual Patient Saf, 43(12), 621-632. (Read full article)
78. Suffoletto B, Yanta J, Kurtz R, Cochran G, Douaihy A, Chung T (2017). Acceptability of an Opioid Relapse Prevention Text-message Intervention for Emergency Department Patients. J Addict Med, 11(6), 475-482. (Read full article)
79. Cochran G, Hruschak V, Bacci JL, Hohmeier KC, Tarter R (2017). Behavioral, mental, and physical health characteristics and opioid medication misuse among community pharmacy patients: A latent class analysis. Res Social Adm Pharm, 13(6), 1055-1061. (Read full article)
80. Cochran G, McCarthy R, Gordon AJ, Tarter RE (2017). Opioid medication misuse among unhealthy drinkers. Drug Alcohol Depend, 179, 13-17. (Read full article)
81. Ylioja T, Cochran G, Chang Y, Tindle HA, Rigotti NA (2017). Postdischarge smoking cessation in subgroups of hospitalized smokers: A latent class analysis. Subst Abus, 38(4), 493-497. (Read full article)
82. Cochran GT, Engel RJ, Hruschak VJ, Tarter RE (2017). Prescription Opioid Misuse Among Rural Community Pharmacy Patients: Pilot Study for Screening and Implications for Future Practice and Research. J Pharm Pract, 30(5), 498-505. (Read full article)
83. Frazier W, Cochran G, Lo-Ciganic WH, Gellad WF, Gordon AJ, Chang CH, Donohue JM (2017). Medication-Assisted Treatment and Opioid Use Before and After Overdose in Pennsylvania Medicaid. JAMA, 318(8), 750-752. (Read full article)
84. Hruschak V Msw Rsw, Cochran G (2017). Psychosocial and environmental factors in the prognosis of individuals with chronic pain and comorbid mental health. Soc Work Health Care, 56(7), 573-587. (Read full article)
85. Cochran G, Rosen D, McCarthy RM, Engel RJ (2017). Risk Factors for Symptoms of Prescription Opioid Misuse: Do Older Adults Differ from Younger Adult Patients? J Gerontol Soc Work, 60(6-7), 443-457. (Read full article)
86. Bahorik AL, Greeno CG, Cochran G, Cornelius JR, Eack SM (2017). Motivation deficits and use of alcohol and illicit drugs among individuals with schizophrenia. Psychiatry Res, 253, 391-397. (Read full article)
87. Cochran G, Gordon AJ, Gellad WF, Chang CH, Lo-Ciganic WH, Lobo C, Cole E, Frazier W, Zheng P, Kelley D, Donohue JM (2017). Medicaid prior authorization and opioid medication abuse and overdose. Am J Manag Care, 23(5), e164-e171. (Read full article)
88. Cochran G, Gordon AJ, Lo-Ciganic WH, Gellad WF, Frazier W, Lobo C, Chang CH, Zheng P, Donohue JM (2017). An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program. Med Care, 55(3), 291-298. (Read full article)
89. Cochran G, Hruschak V, DeFosse B, Hohmeier KC (2016). Prescription opioid abuse: pharmacists' perspective and response. Integr Pharm Res Pract, 5, 65-73. (Read full article)
90. Cochran G, Field C, Foreman M, Ylioja T, Brown CV (2016). Effects of brief intervention on subgroups of injured patients who drink at risk levels. Inj Prev, 22(3), 221-5. (Read full article)
91. Knowlton AR, Weir B, Fields J, Cochran G, McWilliams J, Wissow L, Lawner BJ (2016). Pediatric Use of Emergency Medical Services: The Role of Chronic Illnesses and Behavioral Health Problems. Prehosp Emerg Care, 20(3), 362-8. (Read full article)
92. Cochran G, Bacci JL, Ylioja T, Hruschak V, Miller S, Seybert AL, Tarter R (2016). Prescription opioid use: Patient characteristics and misuse in community pharmacy. J Am Pharm Assoc (2003), 56(3), 248-256.e6. (Read full article)
93. Lo-Ciganic WH, Gellad WF, Gordon AJ, Cochran G, Zemaitis MA, Cathers T, Kelley D, Donohue JM (2016). Association between trajectories of buprenorphine treatment and emergency department and in-patient utilization. Addiction, 111(5), 892-902. (Read full article)
94. Cochran G, Gordon AJ, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter R (2016). Developing a framework of care for opioid medication misuse in community pharmacy. Res Social Adm Pharm, 12(2), 293-301. (Read full article)
95. Cochran G, Field C, DiClemente C, Caetano R (2016). Latent Classes Among Recipients of a Brief Alcohol Intervention: A Replication Analysis. Behav Med, 42(1), 29-38. (Read full article)
96. Gordon AJ, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Kelley D, Donohue JM (2015). Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. J Addict Med, 9(6), 470-7. (Read full article)
97. Cochran G, Rubinstein J, Bacci JL, Ylioja T, Tarter R (2015). Screening Community Pharmacy Patients for Risk of Prescription Opioid Misuse. J Addict Med, 9(5), 411-6. (Read full article)
98. Cochran G, Field C, Lawson K (2015). Pharmacists Who Screen and Discuss Opioid Misuse With Patients: Future Directions for Research and Practice. J Pharm Pract, 28(4), 404-12. (Read full article)
99. Cochran G, Field C, Caetano R (2015). Changes in Classes of Injury-Related Risks and Consequences of Risk-Level Drinking: a Latent Transition Analysis. J Behav Health Serv Res, 42(3), 355-66. (Read full article)
100. Krans EE, Cochran G, Bogen DL (2015). Caring for Opioid-dependent Pregnant Women: Prenatal and Postpartum Care Considerations. Clin Obstet Gynecol, 58(2), 370-9. (Read full article)
101. Cochran G, Stitzer M, Campbell AN, Hu MC, Vandrey R, Nunes EV (2015). Web-based treatment for substance use disorders: differential effects by primary substance. Addict Behav, 45, 191-4. (Read full article)
102. Cochran G, Woo B, Lo-Ciganic WH, Gordon AJ, Donohue JM, Gellad WF (2015). Defining Nonmedical Use of Prescription Opioids Within Health Care Claims: A Systematic Review. Subst Abus, 36(2), 192-202. (Read full article)
103. Cochran G, Stitzer M, Nunes EV, Hu MC, Campbell A (2014). Clinically relevant characteristics associated with early treatment drug use versus abstinence. Addict Sci Clin Pract, 9, 6. (Read full article)
104. Field CA, Cochran G, Caetano R, Foreman M, Brown CV (2014). Postdischarge nonmedical use of prescription opioids in at-risk drinkers admitted to urban level I trauma centers. J Trauma Acute Care Surg, 76(3), 833-9. (Read full article)
105. Cochran G, Field C, Caetano R (2014). Injury-related consequences of alcohol misuse among injured patients who received screening and brief intervention for alcohol: a latent class analysis. Subst Abus, 35(2), 153-62. (Read full article)
106. Cochran G, Roll J, Jackson R, Kennedy J (2014). Health care reform and the behavioral health workforce. J Soc Work Pract Addict, 14(2), 127-40.
107. Field CA, Cochran G, Caetano R (2013). Treatment utilization and unmet treatment need among Hispanics following brief intervention. Alcohol Clin Exp Res, 37(2), 300-7. (Read full article)
108. Cochran G, Field, C (2013). Brief intervention and social work: a primer for practice and policy. Soc Work Public Health, 28(3-4), 248-263.
109. Cochran G, Field C, Lawson K, Erickson C (2013). Pharmacists' Knowledge, Attitudes, and Beliefs Regarding Screening and Brief Intervention for Prescription Opioid Abuse: A Survey of Utah and Texas Pharmacists. J Pharm Health Serv Res, 4, 71-9.
110. Field CA, Cochran G, Caetano R (2012). Ethnic differences in the effect of drug use and drug dependence on brief motivational interventions targeting alcohol use. Drug Alcohol Depend, 126(1-2), 21-6. (Read full article)
111. Thompson SJ, Cochran G, Barczyk AN (2012). Family functioning and mental health in runaway youth: association with posttraumatic stress symptoms. J Trauma Stress, 25(5), 598-601. (Read full article)
112. Parrish DE, von Sternberg K, Velasquez MM, Cochran G, Sampson M, Mullen PD (2012). Characteristics and factors associated with the risk of a nicotine exposed pregnancy: expanding the CHOICES preconception counseling model to tobacco. Matern Child Health J, 16(6), 1224-31. (Read full article)
113. Cochran G, Davis K (2012). Social work and the Uniform Accident and Sickness Policy Provision Law: a pilot project. Soc Work, 57(1), 39-48. (Read full article)
114. Cochran G, Montgomery KL, Bell H (2012). Translating evidence-based practices into policy: a case study in Texas. Soc Work Health Care, 51(5), 383-401. (Read full article)
115. Field CA, Cochran G, Foulkrod K, Brown C (2011). Trauma healthcare providers' knowledge of alcohol abuse. J Trauma, 70(6), 1437-43. (Read full article)
116. Cochran G (2010). Analysis of the Uniform Accident And Sickness Policy Provision Law: lessons for social work practice, policy, and research. Soc Work Health Care, 49(7), 647-68. (Read full article)
117. Cochran G (2010). Social policy advocacy evaluation: A more complete model for social work. Prof Dev (Phila), 13(1), 27-39.
118. Cochran G, Landuyt N (2010). A survey of continuing education programs conducted by Professional Development: The International Journal of Continuing Social Work Education. Prof Dev (Phila), 13(2), 55-72.
119. Cochran G, Montgomery K, Rubin A (2010). Does evidence-based practice influence state legislators’ decision-making process? An exploratory study. J Policy Pract, 9(3), 263-83.
120. Roby J, Cochran G (2007). Child headed households in Mozambique: Towards needs-based policy and practice. Soc Dev Issues, 29(3), 19-32.
121. Cochran G (2005). Investigation of child headed households in Mozambique, Africa.

Book Chapter

1. Gordon AJ, Cochran G, Smid MC, Manhapra A, Kertesz SG (2020). Prescribing, prescription monitoring, and health policy. In Kelly JF, Wakeman S (Eds.), Treating Opioid Addiction. Willowick, Ohio: Springer International.
2. Bryan MA, Hruschak V, Dennis C, Rosen D, Cochran G (2020). The Opioid Crisis. In Franklin C, Allen-Meares P, Detlaff AJ, Gehlert S, Healy LM, Kim JS, Kelly JJ, Kelly MS, Logan SLM, Mizrah T, Pandey S, Reamer F (Eds.), Encyclopedia of Social Work. England: Oxford.
3. Cochran G, Ylioja T (2016). Drug Use and Minority Health in the US: Prevalence, Causes, and Future Directions. In Copeland V (Ed.), Contemporary Issues for People of Color: Surviving and Thriving in the US Today. Santa Barbara, CA: ABC-CLIO.
4. Cochran G, Thompson SJ (2012). Alcohol Abuse Prevention and Treatment in Health Care Settings: Screening and Brief Intervention. In Maars J (Ed.), Alcohol Dependence and Addiction (pp. 55-78). Hauppauge, NY: Nova Science Publishers.

Commentary

1. Cox N, Hohmeier KC, Cernasev A, Field C, Elliott S, LaFleur G, Barland KM, Green M, Gardner JW, Gordon AJ, Cochran G (2024). Engaging community pharmacies in practice-based research: lessons from opioid-focused research. Research in Social and Administrative Pharmacy.
2. White A, Lundahl B, Bryan MA, Okifuji, Smid A, Gordon A, Carlston K, Silipigni J, Abdullah W, Krans E, Kenney A, Cochran G (2022). Pregnancy and the opioid crisis: Heightened effects of COVID-19. J Addict Med.
3. Garets M, Arther S, Kitchens C, Cochran G, Gordon AJ (2019). The 2019 Addiction Health Services Research Conference: Insights, Review, and Abstracts. Under review, . Subst Abus, 40(4), 469-472.

Book Review

1. Cochran G (2011). Book Review. [Review of the book The Practice of Research in Social Work]. Research on Social Work Practice, 21, 121-4.

Editorial

1. Cochran G, Bruneau J, Cox N, Gordon A (2020). Medication Treatment for Opioid Use Disorder and Community Pharmacy: Expanding Care During a National Epidemic and Global Pandemic. 41(3), 269-274.

Letter

1. Cochran G, Brown J, Winhusen J (2024). Letter to Editor responding to “Paths Forward for Clinicians Amidst the Rise of Unregulated Clinical Decision Support Software: Our Perspective on NarxCare [Letter to the editor]. J Gen Intern Med.
2. Aruri M, Cochran G, Pringle J (2020). Role of pharmacists in the opioid use disorder (OUD) crisis [Letter to the editor]. Res Social Adm Pharm, 2, 228-229.
3. Gordon A, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Donohue JM (2016). Treatment Quality for Buprenorphine Care: The Pot at the End of the Rainbow. [Letter to the editor]. J Addict Med, 10(3), 210-1. (Read full article)

Abstract

1. Cochran G, Vanneman M, Gulbransen S, Ransco M, Curtis R, Killam K, Rohm, T (2024). Addressing Racial and Ethnic Disparities through Enhancement of Data Quality.  [Abstract].
2. Hafen, K L, Smid, M, Garets, M, Machado, A, White, A H, Cochran, G (2022). Motivations for Recovery Among Pregnant Individuals With Opioid Use Disorder. [Abstract]. 139, 53s-54s.
3. Hafen K, Smid M, Garets M, Machado A, White A, Cochran G (In Press). Motivations for Recovery among Pregnant Individuals with Opioid Use Disorder. [Abstract].
4. Smid M, Charles J, Cavin T, Cochran G, Varner M, Gordon A (2020). Takes Two to Make Three: Pregnant Women With Substance Use Disorder's Intentions for Partner's Role  [Abstract]. 135(59S).
5. Cochran, G Lo-Ciganic, W-H, Gellad, W, Gordon, AJ, Cole, E, Lobo, C, Frazier, W, Zheng, P, Kelley, D, amp Donohue, JM (In press). Quality Measures of Prescription Opioid Utilization in a Large State Medicaid Program. [Abstract]. Substance Abuse.
6. Sakai, H, Hruschak, V, Cochran, G, amp Copeland, V (In press). Virtual Reality-Based Training for Screening, Brief Intervention, and Referral to Treatment in Social Work Education [Abstract]. Substance Abuse.
7. Cochran G, Rubinstein J, Bacci J, Ylioja T, Tarter R (2016). Community pharmacy and opioid pain medication: Screening patients who misuse or are at risk for misuse; also presented orally at the Association for Medical Education and Research in Substance Abuse 39th National Conference, Washington, DC [Abstract]. Substance Abuse, 37(2), 46A.
8. Cochran G, Gordon A, Field C, Bacci J, Dhital R, Ylioja T, Stitzer M, Kelly T, Tarter R (2016). A continuum of care model for opioid misuse in community pharmacy; also presented orally at the Association for Medical Education and Research in Substance Abuse 39th National Conference, Washington, DC [Abstract]. Substance Abuse, 37(2), 47A.
9. Cochran G, Woo B, Lo-Ciganic WH, Gordon A, Donohue J, Wei-Hsuan L, Gellad W (2015). Defining non-medical use of prescription opioids within health care claims: A systematic review; also presented orally at the Association for Medical Education and Research in Substance Abuse 38th National Conference, San Francisco, CA [Abstract]. Substance Abuse, 36(2), 67A.
10. Cochran G, Field C, Foreman M, Brown C (2015). Effects of brief Intervention on subclasses of injured patients who rink at risk levels; also presented orally at the Association for Medical Education and Research in Substance Abuse 38th National Conference, San Francisco, CA [Abstract]. Substance Abuse, 36(2), 75A.
11. Cochran G, Brodie B, Bell A, Bennett A (2015). Factors associated with opioid overdose resuscitation; also presented orally at the Association for Medical Education and Research in Substance Abuse 38th National Conference, San Francisco, CA [Abstract]. Substance Abuse, 36(2), 48A.
12. Field C, Cochran G, Caetano R (2012). The role of drug use in brief alcohol interventions: A multi-ethnic/racial analysis [Abstract]. Addiction Science and Clinical Practice, 7(Suppl 1), A18.
13. Cochran GT (2011). Latent predictors of change from screening and brief alcohol interventions: A mixture modeling approach; also presented orally at the Texas Research Society on Alcoholism Annual Scientific Meeting, Lubbock, TX [Abstract]. Alcoholism—Clinical and Experimental Research, 35(6), 337A-337A.
14. Parrish DE, von Sternberg K, Cochran G, Sampson M, Mullen P, Velasquez MM (2009). Alcohol and nicotine exposed pregnancies: Common and unique characteristics associated with risk [Abstract]. Alcoholism—Clinical and Experimental Research, 33(6), 344A-344A.

Other

1. Cochran G (July/August 2010). The Promise and Pitfalls of Organizational Change. Nonprofit World (28(4), pp. 7-11).

Report

1. White AH, Garets M, Foringer J, Dahlem CH, Beck MC, Soske J, Barnes J, Eckhardt D, Feldstein K, ODonnell N, Britton J, Lugo H, Filimoeatu L, Labelle CT, Cochran G (2022). Medication for Opioid Use Disorder Toolkit for Peer Recovery Specialists. Charlestown, RI: Association for Multidisciplinary Education and Research in Substance use and Addiction.
2. Archer S, Bryan MA, Garets M, Baylis JB, Charron E, Kelley AT, Foringer J, Kenney A, Pendergrass D, Cooper M, Costanzo S, Muniyappa B, Carlston K, Hill J, Begaye L, Fortenberry KT, Cheng M, Smid MC, Cochran G (2020). Substance Use In Pregnancy: Addiction, Dependence, and Recovery, in Carbon, Emery, and San Juan Counties. Salt Lake City: University of Utah, Program for Addiction Research, Clinical Care, Knowledge, and Advocacy.
3. DiDomenico E, Kelley D, Cole E, Pringle J, Warwick J, Donohue J, Gellad W, Cochran G, Kmic J, Bear T, Chang J, Kim JY, Gordon A (2018). Project Rural Access to MAT in Pennsylvania (RAMP): Mid-Grant Report. Pittsburgh, PA: Medicaid Research Center, University of Pittsburgh..
4. Rosen D, Brusoski M, Engel R, Cochran G (2018). The Integrated Health Care Training Corps: Corps: A collaboration between the University of Pittsburgh School of Social Work and the UPMC Health Plan: Year 3 Report. Pittsburgh: University of Pittsburgh.
5. Donohue J, Cole E, Kim JY, Zheng P, Lo-Ciganic W-H, Gordon A, Gellad A, Cochran G (2017). Report on Opioid Prescribing Quality Measures, Opioid Use, Opioid Use Disorder, and Medication-Assisted Treatment in Pennsylvania Medicaid: 2013-2015. Medicaid Research Center, University of Pittsburgh.
6. Cochran G, Ylioja T, Fisher S (2015). Treatment Guide: Targeted medication therapy management for prescription opioid misuse. Pittsburgh, PA: University of Pittsburgh School of Social Work.
7. Donohue J, Cochran G, Gordon A, Zemaitis M, Gellad W (2013). Report on Opioid Use Disorder and Buprenorphine Use in Pennsylvania Medicaid. Center for Pharmaceutical Policy and Prescribing.
8. Cochran G (2010). The Use of the SEE Data in Texas: The Case of the University of Texas at San Antonio. Austin, TX: Center for Social Work Research, Institute for Organizational Excellence.
9. Cochran G (2010). The Use of the SEE Data in Texas: The Case of the Texas Parks and Wildlife Department. Austin, TX: Center for Social Work Research, Institute for Organizational Excellence.
10. Cochran G, Landuyt N (2010). The Second Annual Survey of Continuing Education Programs Conducted by Professional Development: The International Journal of Continuing Social Work Education. Austin, TX: Center for Social Work Research, Institute for Organizational Excellence.
11. Fong R, Urban B, Cochran G (2008). Evaluation of south Texas coalition against human trafficking (STCAHT). Austin, TX: Center for Social Work Research.
12. Fong R, Urban B, Cochran G (2008). Evaluation of Catholic Charities of San Antonio’s human trafficking trainings and presentations. Austin, TX: Center for Social Work Research.
13. Cochran G (2008). CHIP: A Utah success story. Salt Lake City, UT: Voices for Utah Children.
14. McRoy R, Ayers-Lopez S, Wallace M, Fong R, Schwartz A, Leonardo A, Simons O, Popham A, Wheeler K, Boyd K, Edwards E, Tostada B, Holmes T, Cochran G, Kim S, Steinley-Bungarner M, Naik R, Cody P, Barczyk A, Burt B (2008). Adoptive and foster couples retreat and support network program report 2007-2008. Austin, TX: Center for Social Work Research.
15. McRoy R, Ayers-Lopez S, Wallace M, Fong R, Schwartz A, Leonardo A, Simons O, Popham A, Wheeler K, Boyd K, Edwards E, Tostada B, Holmes T, Cochran G, Kim S, Steinley-Bungarner M, Naik R, Cody P, Barczyk A, Burt B (2008). Adoptive and foster couples retreat and support network program report: Part two. Austin, TX: Center for Social Work Research.
16. Harris N, Frost CJ, Lundahl B, Yaffe J, Cochran G, Moran M, Smith R (2005). Salt Lake City Weed and Seed: Final report. Salt Lake City, UT: Social Research Institute, University of Utah.

Video/Film/CD/Web/Podcast

1. Cochran G (2018). Improving Opioid Addiction Treatment for Pregnant Women [Podcast]. Journal of Addiction Medicine. Available: https://journals.lww.com/journaladdictionmedicine/pages/podcastepisodes.aspx?podcastid=1.

• SUBLIME - Study of Utahns' Beliefs and Life Experiences with Integrative Medicine